BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 03/23/2015
Entire Document
 
7

 

BioLineRx Ltd.
CONSOLIDATED CASH FLOW STATEMENTS
 
   
Year ended December 31,
   
Convenience
 translation
 into USD
 
   
2012
   
2013
   
2014
   
2014
 
   
NIS in thousands
   
In thousands
 
APPENDIX
                       
                         
Adjustments required to reflect net cash used in operating activities:
                       
Income and expenses not involving cash flows:
                       
Depreciation and amortization
    1,524       1,147       960       247  
Write-off of intangible assets
    -       137       377       97  
Retirement benefit obligations
    60       9       (152 )     (39 )
Long-term prepaid expenses
    -       35       (21 )     (6 )
Exchange differences on cash and cash equivalents
    (172 )     2,358       (934 )     (240 )
           Warrant issuance costs
    1,204       470       -       -  
           Gain on adjustment of warrants to fair value
    (7,265 )     (5,169 )     (12,354 )     (3,177 )
Commitment fee paid by issuance of share capital
    880       -       1,040       267  
Share-based compensation
    3,138       3,040       3,772       970  
Interest and exchange differences on short-term deposits
    1,547       1,424       (9,968 )     (2,563 )
Interest and linkage differences on bank loan
    20       (10 )     -       -  
Interest and exchange differences on restricted deposits
    8       40       (71 )     (18 )
      944       3,481       (17,351 )     (4,462 )
                                 
Changes in operating asset and liability items:
                               
Decrease in trade accounts receivable and other receivables
    1,454       913       286       74  
Increase (decrease) in accounts payable and accruals
    (1,273 )     (13,420 )     302       78  
      181       (12,507 )     588       152  
                                 
      1,125       (9,026 )     (16,763 )     (4,310 )
                                 
Supplementary information on investing and financing activities not involving cash flows:
                               
Credit received in connection with purchase of property and equipment
    10       -       554       142  
                                 
Supplementary information on interest received in cash
    1,720       503       348       90  

8